A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.
Ng
Kimberly
K
Deaprtment of Radiation Oncology, Dana Farber Cancer Institute Boston, Massachusetts, USA.
Nitta
Masayuki
M
Hu
Lauren
L
Kesari
Santosh
S
Kung
Andrew
A
D'Andrea
Alan
A
Chen
Clark C
CC
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D018929:Cell Culture Techniques; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005909:Glioblastoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D051379:Mice; D011480:Protease Inhibitors / Q000627:therapeutic use*; D046988:Proteasome Endopeptidase Complex / Q000235:genetics*; D011719:Pyrazines / Q000627:therapeutic use; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000502:physiology*; D000077204:Temozolomide; D014407:Tumor Cells, Cultured
D018906:Antineoplastic Agents, Alkylating; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D034741:RNA, Small Interfering; D000069286:Bortezomib; D003606:Dacarbazine; D046988:Proteasome Endopeptidase Complex; D000077204:Temozolomide